COVID-19 Vaccine Perception and Hesitancy Among Patients With Sickle Cell Disease in the Western Region of Saudi Arabia.
COVID-19 Vaccine Perception and Hesitancy Among Patients With Sickle Cell Disease in the Western Region of Saudi Arabia.
复制标题
DOI：
10.7759/cureus.21026
复制
发表时间：
2022-01
期刊：
影响因子：
--
通讯作者：
Radhwi O
中科院分区：
文献类型：
--
作者：
Jan H;Waheeb A;AlAhwal H;Almohammadi A;Al-Marzouki A;Barefah A;Bahashawan S;Radhwi O
背景：在 2019 年冠状病毒病 (COVID-19) 大流行时代，通过疫苗接种保护公众的竞赛仍在继续。鉴于镰状细胞病 (SCD) 患者的医疗需求和免疫接种的常见副作用，需要特别考虑，从而影响他们的决定。因此，我们的目的是评估该人群对 COVID-19 疫苗接种的看法和犹豫，并探讨疫苗接种决策时的可能因素。方法：本次横断面电话访谈研究于 2021 年 5 月 10 日至 20 日期间进行。调查问卷由医务人员进行。参与者都是沙特阿拉伯吉达阿卜杜勒阿齐兹国王大学医院的 SCD 患者。 结果：在 346 名患者中，147 名患者同意参加。只有 52 名（35.37%）患者接受了至少一剂全国可用疫苗，并且没有报告严重副作用。在未接种疫苗的参与者中，45 名患者 (47.8%) 尚未做出决定。报道最多的犹豫原因是担心像他们的熟人那样出现并发症，以及担心接种疫苗后出现脑血栓。结论：不幸的是，在我们的研究中，由于犹豫不决，接种疫苗的 SCD 患者数量很少。这是一个重大障碍，在与 SCD 患者进行适当互动时需要适当解决。不存在重大副作用和血管闭塞危机是令人放心的。
Background: In the era of the coronavirus disease-2019 (COVID-19) pandemic, the race toward shielding the public through vaccination is still going. Patients with sickle cell disease (SCD) require special consideration given their medical needs and the common side effects of immunization, affecting their decision. Therefore, we aimed to assess the perception and hesitancy toward COVID-19 vaccination in this population and explore the possible factors when it comes to vaccination decisions. Methods: The present cross-sectional phone interview study was conducted between May 10 and 20, 2021. The questionnaire was administered by the medical staff. The participants were all patients with SCD presented to King Abdulaziz University Hospital in Jeddah, Saudi Arabia. Results: Out of 346 patients, 147 patients agreed to participate. Only 52 (35.37%) patients received at least one dose of the nationally available vaccines, and there were no reported serious side effects. Among the unvaccinated participants, 45 patients (47.8%) were undecided. The most reported reasons for hesitancy were the fear of developing complications as their acquaintance had and the fear of developing brain blood clots post vaccination. Conclusions: The number of vaccinated patients with SCD was unfortunately low in our study, secondary to hesitancy. This represents a significant barrier and needs to be tackled appropriately at any proper interaction with a patient with SCD. The absence of major side effects and vaso-occlusive crises is assuring.